XML 42 R26.htm IDEA: XBRL DOCUMENT

Equity - contributed equity

12 Months Ended

Jun. 30, 2023

Note 2

. Equity - contributed equity


	Consolidated
	2023		2022		2023		2022
	Shares		Shares		$		$

Ordinary shares - fully paid		228,029,114		138,755,376		97,452,246		84,480,249

Movements in ordinary share capital


Details	Date		Shares		Issue price		$

Balance		1 July 2021		132,012,209				80,290,062
Issued on conversion of options		15 December 2021		25,000	$	0.6680		16,700
Conversion of Triaxial Convertible Note		5 May 2022		1,855,357	$	0.2500		464,000
ATM issue of shares No. 1		24 May 2022		10,000	$	0.8260		8,256
ATM issue of shares No. 2		2 June 2022		10,000	$	0.8020		8,025
ATM issue of shares No. 3		6 June 2022		88,710	$	0.8370		74,258
ATM issue of shares No. 4		9 June 2022		603,500	$	0.8400		507,035
ATM issue of shares No. 5		14 June 2022		75,940	$	0.8240		62,583
ATM issue of shares No. 6		15 June 2022		2,000	$	0.8300		1,661
ATM issue of shares No. 7		20 June 2022		4,072,660	$	0.8690		3,540,403
Less: share issue transaction costs				—	$	0.0000		(492,735	)


Balance		30 June 2022		138,755,376				84,480,249

ATM issue of shares No. 8		7 July 2022		573,370	$	0.7102		407,201
ATM issue of shares No. 9		8 August 2022		8,561,490	$	0.3316		2,839,346
ATM issue of shares No. 10		9 August 2022		10,000	$	0.2723		2,723
ATM issue of shares No. 11		10 August 2022		158,020	$	0.2465		38,949
ATM issue of shares No. 12		11 August 2022		330,960	$	0.2413		79,868
ATM issue of shares No. 13		12 August 2022		1,247,440	$	0.2469		308,050
ATM issue of shares No. 14		12 September 2022		651,030	$	0.2211		143,964
ATM issue of shares No. 15		13 September 2022		28,350	$	0.2187		6,200
Shares issued to Scientific Advisory Board		14 September 2022		60,000	$	0.2100		12,600
ATM issue of shares No. 16		7 October 2022		736,760	$	0.1789		131,797
ATM issue of shares No. 17		28 October 2022		12,296,180	$	0.1865		2,293,288
ATM issue of shares No. 18		11 January 2023		20,000	$	0.1380		2,761
Professional and sophisticated investors placement – 1st tranche		16 January 2023		25,387,018	$	0.1100		2,792,572
Professional and sophisticated investors placement – 2nd tranche		2 8 February 2023		15,522,075	$	0.1100		1,707,428
Share Placement Plan		3 March 2023		23,691,045	$	0.1100		2,606,000
Less: share issue transaction costs				—	$	0.0000		(400,750	)


Balance				228,029,114				97,452,246

Ordinary shares

Ordinary

shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

buy-back

There is no current

on-market

buy-back.

Capital risk management

The consolidated entity’s objectives when managing capital are to safeguard its ability to continue as a going concern, so that it

can

provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital.

Capital is regarded as total equity, as recognized in the statement of financial position, plus net debt. Net debt is calculated as total borrowings less cash and cash equivalents.

The capital structure of the consolidated entity consists of cash and cash equivalents and equity attributable to equity holders. The overall strategy of the consolidated entity is to continue its drug development programs, which depends on raising sufficient funds, through a variety of sources including issuing of additional share capital, as may be required from time to time.

The capital risk management policy remains unchanged from the prior year.